Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing Pharmaceutical Group got acceptance for the TQB3454 tablet from China's National Medical Products Administration.
The acceptance is for use of the drug to treat advanced biliary tract cancer harboring IDH1 mutations, according to a Friday Hong Kong bourse filing.